Compare Cenovus Energy Inc (CVE) vs Revvity Inc (RVTY) Price & Performance

Cenovus Energy (CVE) trades at $31.49, up 2.81% with bullish technical momentum. The stock shows strong fundamentals with a P/E of 12.43 and EV/EBITDA of 6.17, trading near 52-week highs. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. Operating cash flow remains robust at $8.23B despite negative net cash flow in 2025. Analyst consensus is mixed with 40.7% buy ratings amid positive media coverage highlighting growth potential.

CVE presents a compelling value opportunity with attractive valuation metrics and improving profitability. The main investment thesis centers on earnings growth recovery and operational efficiency gains. Key risks include oil price volatility and execution challenges in capital expenditure management. Institutional ownership trends and recent analyst upgrades support a cautiously optimistic outlook for medium-term appreciation.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.